Phio Pharma's New Preclinical Data Shows PH-894 Enhances Activity of Cancer CAR-T Cells

  • Phio Pharmaceuticals Corp PHIO presented new preclinical data showing that silencing BRD4 with PH-894 can improve the quality and potency of HER2-targeted CAR-T cells in a CAR-T expansion model. 
  • These new data will be presented at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting.
  • Related: Phio Pharma Shares Shine After Positive PH-894 Preclinical Data At AACR Presentation.
  • Results showed that PH-894 reduced the expansion-associated production of BRD4 and BRD4-regulated genes and mitigated the production of inhibitory receptors and markers of T cell exhaustion.
  • Additionally, PH-894 preserved putative T cell stem-cell memory and central memory, phenotypes associated with cell persistence, on HER2-CAR-T cells that were otherwise depleted by cell expansion without PH-894.
  • Price Action: PHIO shares are down 0.25% at $0.71 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsPreclinical Phase
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!